Staff

Amarantus Signs Non-Binding Term Sheet to Divest Cutanogen Corporation in Exchange for the Extinguishment of Potential $21M+ in Liabilities

Board Member/Acting CEO Provides Shareholder UpdateSale of Engineered Skin Substitute (ESS) subsidiary, Cutanogen Corporation.Emphasis placed on advancing Elto Pharma, Inc....

Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., to Present SP-102 (SEMDEXA™) Efficacy and Safety Data from its Pivotal Phase 3 Clinical Trial Program for Sciatica Pain Management at the 24th Annual Meeting of American Society of Interventional Pain Physicians (ASIPP) in Las Vegas, NV.

Vir Biotechnology Announces New Data From the MARCH Hepatitis B Trial, Unveils New Hepatitis D Clinical Program and Highlights Broad Hepatitis Portfolio at Virtual Hepatitis Portfolio R&D Day

SCYNEXIS Presents Data Analyses Showing Ibrexafungerp’s Potential to Fight Invasive Candidiasis and Candidemia, Including Infections Caused by Candida Auris, During the 32nd Annual European Congress of Clinical Microbiology & Infectious Diseases

error: Content is protected !!